HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

To report the 96-week outcomes from HAWK and HARRIER. Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neovascular age-related macular degeneration (nAMD). Treatment-naïve e...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 128; no. 1; p. 89
Main Authors:	Dugel, Pravin U, Singh, Rishi P, Koh, Adrian, Ogura, Yuichiro, Weissgerber, Georges, Gedif, Kinfemichael, Jaffe, Glenn J, Tadayoni, Ramin, Schmidt-Erfurth, Ursula, Holz, Frank G
Format:	Journal Article
Language:	English
Published:	United States 01.01.2021
Subjects:	Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Follow-Up Studies Humans Macula Lutea - pathology Prospective Studies Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins - administration & dosage Time Factors Tomography, Optical Coherence - methods Treatment Outcome Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!